A commanding management team that have brought numerous products to market
The founders of TesoRx bring vast experience in both pharmaceutical research and business to their leadership of the company’s executive management team. With a strong track record of taking products from bench to market, establishing pharmaceutical manufacturing facilities and managing successful companies, they are well positioned to deliver innovative biotech products to market.
Ramachandran “TR” Thirucote, Ph.D. — Chairman & CEO
Dr. Ramachandran “TR” Thirucote is a dynamic executive with 30 years of hands-on experience and management in the design and development of various dosage forms for the pharmaceutical and biopharmaceutical industries. He has successfully developed and helped launch several products, including solid dosage forms such as tablets and capsules, injectable and oral dosage forms, ointments and creams, as well as novel forms such as controlled and nasal drug delivery systems.
Prior to establishing TesoRx, TR was vice president, pharmaceutical sciences at ROXRO Pharma, where he was primarily responsible for developing SPRIX™, a nasal spray developed for use in post-operative pain treatment, which was approved by the US FDA in May 2010. His professional experience also includes senior positions at SRI (formerly Stanford Research Institute) International, Agouron Pharmaceuticals (now Pfizer), Thermedics and Astra-IDL. A well-known and published scientist, TR holds eight patents and speaks regularly at national and international symposia. He is an active participant and industry consultant to the US National Institute of Health (NIH) and a member of the Special Emphasis Review Panel for the National Institute of Allergy and Infectious Diseases (NIAID).
Guru Betageri, Ph.D. — Co-Founder & Chief Scientific Advisor
Dr. Guru Betageri, an AAPS Fellow, is a leading expert in the area of liposome, proliposome and lipid based drug delivery systems. As professor of pharmaceutical sciences at Western University of Health Sciences (WesternU), he currently teaches preformulation, product development and novel drug delivery systems to graduate students. He also conducts research work supported by federal agencies as well as numerous pharmaceutical companies, especially in the area of solid dosage forms, and has been instrumental in the formulation and development of several products now on the market. TesoRx has licensed the patents developed by Guru at WesternU and continues to collaborate with the university for the ongoing development of TSX-002 and other products.
Guru has published more than 80 original research papers in refereed journals and presented more than 150 papers at national and international meetings, and is the co-author of the book “Liposome Drug Delivery” as well as several chapters of other books. He has been invited to speak at various National and International Conferences and Pharmaceutical companies. He has also authored numerous US patents. He is a reviewer or member of the editorial board for more than 12 pharmaceutical journals.
Willem A Robberts C.A. (SA), M.Comm(RAU) — President & CFO
Will Robberts is an investor, entrepreneur and seasoned C-level executive with extensive experience in a variety of industries. He has completed numerous M&A transactions in industries ranging from software and professional services to pharmaceuticals and real estate.
Before co-founding TesoRx, Will founded Kempton Investments, a private firm focusing on investments in the technology, life sciences and real-estate. His career has also encompassed several C-level positions in which his management and deal-making skills drove exceptional value for stockholders. Most recently, as president of LiveNote, he grew the company organically and through acquisition to become the most widely used litigation software in the legal industry before selling it to Thomson Reuters. Will began his career with KPMG Corporate Finance, where he focused on M&A transactions, divestitures, fundraisings and IPOs in the technology and media markets.
Michael G Oefelein MD, FACS - Chief Medical Officer
Dr. Michael Oefelein is a board certified physician and a Fellow of the American College of Surgeons with extensive experience in the pharmaceutical and the device industry—including dermatology, urology, oncology, ophthalmology and plastic and bariatric surgery. He has authored nearly 100 peer reviewed publications, and he has delivered numerous scientific presentations at regional, national and international venues. He has designed and executed clinical trials for a number of purposes, including: differentiation, pharmaco- economic, value, label change, safety, drug-drug interaction, dose-ranging, IND/NDA and IDE/PMA. Dr. Oefelein has helped develop several Genitourinary oncology drugs: Degarelix, Zometa and Apaziquone, and non-oncology drugs: Levaquin, Botox, Serenity-120, and Devices: Seriscaffold, Breast implants, HA-fillers and surgical navigations systems. He is an active member of numerous medical societies, including the Society of Urological Oncology, SUFU, AUA, American College of Surgeons and Laparoscopic surgeons. Dr. Oefelein has led several device (Silicone breast implants, Lap-Band) and pharmaceutical (Bimatoprost, Latisse, Sanctura XR) safety evaluations. Dr Oefelein has developed scientific content for, and he has led, numerous advisory board meetings, and he has translated the meeting output into enduring materials. He has developed numerous publication and differentiation plans for a wide range of pharmaceutical and device assets. In summary, Dr. Oefelein has diverse academic, pharmaceutical and device experiences, and a track record of success.